Вы здесь

    Дугина А.Е. Селективные агонисты α2-адренорецепторов в лечении глаукомы.

    Дугина Алевтина Евгеньевна (Центр микрохирургии глаза Дорожной клинической больницы им. Н.А. Семашко, г. Москва, Россия).

    Selective of α2-adrenoceptor agonists in glaucoma treatment

    Dugina Alevtina, PhD. Ophthalmologist in Eye microsurgery center in N.A. Semashko clinical hospital of Russian Railways (Sevastopolskaya st., 23. Moscow, Russian Federation, 109386)

    Conflicts of Interest and Source of Funding: none declared.

    В обзоре рассматриваются ключевые фармакотерапевтические характеристики селективных агонистов адренорецепторов, включая аффинность к адренорецепторам, гипотензивный механизм и возможные способы нейропротекторного действия.

    Также приведено сравнение профилей эффективности и безопасности бримонидина и других антиглаукомных препаратов.

    Ключевые слова: селективные агонисты адренорецепторов, глаукома, нейропротекция, бримонидин.

    The review focuses on key pharmacotherapeutic characteristics of selective adrenoceptor agonists, including their receptor selectivity, IOP-lowering mechanism of action and potential neuroprotective activities.

    As well, comparison of efficacy and safety profiles of brimonidine and other antiglaucoma drugs is made.

    Key words: selective adrenoceptor agonist, glaucoma, neuroprotection, brimonidine

    Открой и читай статью!


    1. Rahman M.Q., Ramaesh K., Montgomery D.M. Brimonidine for glaucoma. Expert Opin Drug Saf. 2010; 9: 483-491.

    2. Jimmy D.B., Siret D.J. Clinical ocular pharmacology. Elsevier Health Sciences; 2008; p. 793.

    3. Sponsel W.E., Paris G., Trigo Y., Pena M., Weber A., Sanford K., McKinnon S. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. Am J Ophthalmol. 2002; 133: 11-18.

    4. Abud T.B., Scuoteguazza F.M., Oliveira E.S., Abud J.F., Prata Junior J.A. Hypotensive effect of three different formulations of brimonidine tartrate in normal eyes. Arq Bras Oftalmol. 2013; 76: 69-71.

    5. Kim C.Y., Hong S., Seong G.J. Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther. 2007; 23: 481-486.

    6. Zhang N., Kannan R., Okamoto C.T., Ryan S.J., Lee V.H., Hinton D.R. Characterization of brimonidine transport in retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2006; 47: 287-294.

    7. Acheampong A.A., Shackleton M., John B., Burke J., Wheeler L., Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab Dispos. 2002; 30: 421-429.

    8. Acheampong AA, Shackleton M, Tang-Liu DD. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos. 1995; 23: 708-712.

    9. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med. 2009; 15: 89-100.

    10. Das A., Sribnick E.A., Wingrave J.M., Del Re A.M., Woodward J.J., Appel S.H., Banik N.L., Ray S.K. Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4.1) motoneurons exposed to glutamate: calpain inhibition provides functional neuroprotection. J Neurosci Res. 2005; 81: 551-562.

    11. Sharma A.K., Rohrer B. Calcium-induced calpain mediates apoptosis via caspase-3 in a mouse photoreceptor cell line. J Biol Chem. 2004; 279: 35564-35572.

    12. Brennan A.M., Suh S.W., Won S.J., Narasimhan P., Kauppinen T.M., Lee H., Edling Y., Chan P.H., Swanson R.A. NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation. Nat Neurosci. 2009; 12: 857-863.

    13. Sattler R., Xiong Z., Lu W.Y., Hafner M., MacDonald J.F., Tymianski M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science. 1999; 284: 1845-1848.

    14. Lee D., Kim K., Noh Y.H., Chai S., Lindsey J.D., Ellisman M.H., Weinreb R.N., Ju W.-K. Brimonidine blocks glutamate excitotoxicity-induced oxidative stress and preserves mitochondrial transcription factor a in ischemic retinal injury. PLoS One. 2012; 7.

    15. Starke K. Presynaptic autoreceptors in the third decade: focus on alpha2-adrenoceptors. J Neurochem. 2001; 78: 685-693.

    16. Boehm S. Presynaptic alpha2-adrenoceptors control excitatory, but not inhibitory, transmission at rat hippocampal synapses. J. Physiol. 1999; 519 Pt 2: 439-449.

    17. Bünemann M., Bücheler M.M., Philipp M., Lohse M.J., Hein L. Activation and deactivation kinetics of alpha 2A- and alpha 2C-adrenergic receptor-activated G protein-activated inwardly rectifying K+ channel currents. J Biol Chem. 2001; 276: 47512-47517.

    18. Delaney A.J., Crane J.W., Sah P. Noradrenaline modulates transmission at a central synapse by a presynaptic mechanism. Neuron. 2007; 56: 880-892.

    19. Dong C.J., Guo Y., Agey P., Wheeler L., Hare W.A. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci. 2008; 49: 4515-4522.

    20. Hare W.A., WoldeMussie E., Lai R.K., Ton H., Ruiz G., Chun T., Wheeler L. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Invest Ophthalmol Vis Sci. 2004; 45: 2625-2639.

    21. Ju W.K., Kim K.Y., Angert M., Duong-Polk K.X., Lindsey J.D., Ellisman M.H., Weinreb R.N. Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. Invest Ophthalmol Vis Sci. 2009; 50: 707-716.

    22. Sattler R., Tymianski M. Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol Neurobiol. 2001; 24: 107-129.

    23. WoldeMussie E., Yoles E., Schwartz M., Ruiz G., Wheeler L.A. Neuroprotective effect of memantine in different retinal injury models in rats. J Glaucoma. 2002; 11: 474-480.

    24. Lambert W.S., Ruiz L., Crish S.D., Wheeler L.A., Calkins D.J. Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons. Mol Neurodegener. 2011; 6: 4.

    25. López-Herrera M.P.L., Mayor-Torroglosa S., de Imperial J.M., Villegas-Pérez M.P., Vidal-Sanz M. Transient ischemia of the retina results in altered retrograde axoplasmic transport: neuroprotection with brimonidine. Exp Neurol. 2002; 178: 243-258.

    26. Donello J.E., Padillo E.U., Webster M.L., Wheeler L.A., Gil D.W. Alpha(2)-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther. 2001; 296: 216-223.

    27. Lai R.K., Chun T., Hasson D., Lee S., Mehrbod F., Wheeler L. Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis Neurosci. 2002; 19: 175-185.

    28. Hernández, M., Urcola, J.H., Vecino, E. Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments. Exp. Eye Res. 2008; 86: 798-806.

    29. WoldeMussie E., Ruiz G., Wijono M., Wheeler L.A. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001; 42: 2849-2855.

    30. DuBiner H.B., Mroz M., Shapiro A.M., Dirks M.S. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. Clin Ther. 2001; 23: 1969-1983.

    31. Chen M.J., Chou J.C., Hsu W.M., Liu J.H. The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients. J Chin Med Assoc. 2003; 66: 276-281.

    32. Javitt J.C., Schiffman R.M. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I. J Glaucoma. 2000; 9: 224-234.

    33. Whitson J.T., Henry C., Hughes B., Lee D.A., Terry S., Fechtner R.D. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Glaucoma. 2004; 13: 168-173.

    34. Melamed S., David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. Clin Ther. 2000; 22: 103-111.

    35. Einarson T.R., Kulin N.A., Tingey D., Iskedjian M. Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma. Clin Ther. 2000; 22: 1502-1515.

    36. Cantor L.B., Hoop J., Katz L.J., Flartey K. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure. Clin Ther. 2001; 23: 1032-1039.

    37. Javitt J., Goldberg I. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II. J Glaucoma. 2000; 9: 398-408.

    38. Schuman J.S. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol. 1996; 41 Suppl 1: 27-37.

    39. Camras C.B., Sheu W.P., United States Latanoprost-Brimonidine Study Group. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. J Glaucoma. 2005; 14: 161-167.

    40. Kampik A., Arias-Puente A., O'Brart D.P., Vuori M.L., European Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma. 2002; 11: 90-96.

    41. Stewart W.C., Day D.G., Stewart J.A., Holmes K.T., Leech J.N., Rowan C.T., Schwartz G.F. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2000; 16: 557-564.

    42. Thomas R., Parikh R., Muliyil J., George R., Paul P., Abraham L.M. Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes. Indian J Ophthalmol. 2003; 51: 123-128.

    43. Craven E.R., Walters T.R., Williams R., Chou C., Cheetham J.K., Schiffman R. Combigan Study Group. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2005; 21: 337-348.

    44. Centofanti M., Manni G., Gregori D., Cocco F., Lorenzano D., Bucci M.G. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma. Graefes Arch Clin Exp Ophthalmol. 2000; 238: 302-305.

    45. Simmons S.T., Alphagan/Trusopt Study Group. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther. 2001; 23: 604-619.

    46. Bozić M., Hentova-Senćić P., Kontić D., Marković V., Marjanović I. Prevention of intraocular pressure elevation after argon laser trabeculoplasty in primary open angle glaucoma. Srp Arh Celok Lek. 2011; 139: 12-17.

    47. Singhal D., Desai R., Desai S., Shastri M., Saxena D. Use of topical brimonidine to prevent intraocular pressure elevations following Nd: YAG-laser posterior capsulotomy. J Pharmacol Pharmacother. 2011; 2: 104-106.

    48. Coppens G., Stalmans I., Zeyen T., Casteels I. The safety and efficacy of glaucoma medication in the pediatric population. J Pediatr Ophthalmol Strabismus. 2009; 46: 12-18.

    49. Lai Becker M., Huntington N., Woolf A.D. Brimonidine tartrate poisoning in children: frequency, trends, and use of naloxone as an antidote. Pediatrics. 2009; 123: 305-311.

    50. Moore W., Nischal K.K. Pharmacologic management of glaucoma in childhood. Paediatr Drugs. 2007; 9: 71-79.

    51. Salim S. Glaucoma in pregnancy. Curr Opin Ophthalmol. 2014; 25: 93-97.

    52. Razeghinejad M.R., Tania T.T.Y., Fudemberg S.J., Katz L.J. Pregnancy and glaucoma. S

    Национальный журнал глаукома, 3, 2014, стр. 95-100 (glaucomajournal.ru).


    Люксфен, Luxfen

    Материал для публикации на портале Орган зрения organum-visus.com любезно предоставила компания Валеант.

    Внимание! Данная информация предназначена исключительно для ознакомления.

    Любое применение опубликованного материала возможно только после консультации со специалистом.

    Разрешается некоммерческое цитирование материалов данного раздела при условии полного указания источника заимствования: имени автора и WEB-адреcа данного раздела www.organum-visus.com

    Материал и дизайн рисунка подготовил: Голубев Сергей Юрьевич.